Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.

ABSTRACT:

Background

The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC tumors, with unexplored clinical and molecular correlates.

Experimental design

We leveraged sequencing data from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium 3 (CPTAC-3), and the (Australian Pancreatic Cancer Genome Initiative) PACA-AU cohorts to characterize MGMT-silenced PAC. Genomic, transcriptomic, methylation, and clinical data were investigated, and findings were validated in silico using methylation, transcriptomic and drug sensitivity data from Cancer Cell Line Encyclopedia (CCLE) project, and in a real-worl

SUBMITTER: Nichetti F 

PROVIDER: S-EPMC11609587 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature